IDIA.SW Idorsia Ltd
SIXHealthcareAs of 2026-06-01 05:22
Valuation
View DetailsP/E (TTM)
-5.17
PEG
—
P/B
-0.97
P/S
4.43
EV/EBITDA
-15.28
DCF Value
—
FCF Yield
-14.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.9%
Operating Margin
-95.6%
Net Margin
-100.7%
ROE
19.2%
ROA
-45.9%
ROIC
-62.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $57.4M | $-45.7M | $-0.18 |
| Q4 2025 | $48.0M | $-78.0M | $-0.31 |
| Q3 2025 | $41.5M | $-85.7M | $-0.40 |
| Q2 2025 | $72.2M | $-11.4M | $-0.06 |
Latest News
Listing Info
Market
US
Exchange
SIX
Currency
USD
Sector
Healthcare
Industry
Biotechnology
Country
CH
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.